Matthew R. Smith

Active 1999–2026

Also published as
Matthew R Smith
167
Papers
43,788
Citations
99
h-index
157
i10-index

Citations

Citations per year for Matthew R. Smith1938: 1 citations1994: 1 citations1998: 2 citations2000: 5 citations2001: 23 citations2002: 48 citations2003: 51 citations2004: 70 citations2005: 94 citations2006: 107 citations2007: 154 citations2008: 276 citations2009: 231 citations2010: 317 citations2011: 362 citations2012: 273 citations2013: 433 citations2014: 422 citations2015: 356 citations2016: 334 citations2017: 383 citations2018: 396 citations2019: 1,259 citations2020: 1,434 citations2021: 1,293 citations2022: 964 citations2023: 749 citations2024: 1,271 citations2025: 552 citations2026: 23 citations1939–1993: no citations, so these years are not shown1995–1997: no citations, so these years are not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,657 citing papers, 25.3% of this breakdownChina: 1,062 citing papers, 7.3% of this breakdownUnited Kingdom: 1,012 citing papers, 7% of this breakdownCanada: 786 citing papers, 5.4% of this breakdownItaly: 709 citing papers, 4.9% of this breakdownGermany: 687 citing papers, 4.8% of this breakdownFrance: 594 citing papers, 4.1% of this breakdownAustralia: 568 citing papers, 3.9% of this breakdownJapan: 413 citing papers, 2.9% of this breakdownSpain: 389 citing papers, 2.7% of this breakdownBelgium: 359 citing papers, 2.5% of this breakdownNetherlands: 350 citing papers, 2.4% of this breakdown
0%25.3%Other 26.8%

Fields

  • Medicine68%
  • Biochemistry, Genetics and Molecular Biology15.7%
  • Engineering4.6%
  • Environmental Science2.8%
  • Agricultural and Biological Sciences2.2%
  • Nursing1.6%
  • Other5.1%

Topics

  • Prostate Cancer Treatment and Research13.7%
  • Prostate Cancer Diagnosis and Treatment7.6%
  • Cancer Cells and Metastasis4.1%
  • Bone health and treatments4%
  • Radiopharmaceutical Chemistry and Applications3.5%
  • Cancer Genomics and Diagnostics3.1%
  • Other64%

Coauthors

All papers

Open in search
  1. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 904

  2. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Howard Gurney, Elizabeth Hovey, Anthony M. Joshua, Matos Marco, Gavin Marx, Michelle Morris, Siobhan Ng, David Pook, Shahneen Sandhu, Ali Tafreshi, Thean Hsiang Tan, Tsvetanka Tosheva, Livia Andrade, Felipe Melo Cruz, Luiza Dib Batista Bugiato Faria, J. M. L. Figueiredo, Fábio Franke, Andrea Juliana Gomes, Ariel Galapo Kann, Celio Kussumoto, Suelen Patrícia dos Santos Martins, André M. Murad, Hélio Pinczowski, Giovani Thomaz Pioner, Luís Ferreira Pires, Daniel D’Almeida Preto, Gisele Marinho dos Santos, Eduardo Silva, Jamile Silva, Luciano de Souza Viana, Karina Vianna, Adriano Augusto Peclat de Paula, Zhiwen Chen, Kim Chi, Urban Emmenegger, Neil Fleshner, Sunil Parimi, Fred Saad, Francisco Vera-Badillo, Hongqian Guo, Hong Luo, Lulin Ma, Mingxing Qui, Wei Xue, Guo Yonglian, Lei Li, Jinxian Pu, Song Zheng, Qing Zou, Miloš Broďák, Milan Hora, Vladimír Šámal, Vladimír Študent, J Vaňásek, Emmanuelle Bompas, Philippe Barthélémy, Delphine Borchiellini, Aude Fléchon, Hakim Mahammedi, Guilhem Roubaud, Antoine Thiery-Vuillemin, Diégo Tosi, Dominique Spaëth, Carole Hélissey, Martin Boegemann, Susan Feyerabend, Eva Hellmis, Martin Schostak, Gerhardt Attard, Anna Lydon and 141 more - Journal of Clinical Oncology 2023 cited by 319

  3. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 cited by 2,795

  4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 1,354

  5. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,326

  6. Isolation of rare circulating tumour cells in cancer patients by microchip technology

    Authors: , , , , , , , , , , , , , , - Nature 2007 cited by 3,556

  7. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 922

  8. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 199

  9. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  10. Climate Change and Global Food Systems: Potential Impacts on Food Security and Undernutrition

    Authors: , , , , , , , - Annual Review of Public Health 2017 cited by 1,072

  11. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 215

  12. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

    Authors: , , , , , , , , , , , , , - The Lancet 2011 cited by 1,965

  13. Apalutamide and Overall Survival in Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 290

  14. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D'Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich and 34 more - The Lancet Oncology 2022 cited by 186

  15. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Science 2015 cited by 724

  16. Global trends in dietary micronutrient supplies and estimated prevalence of inadequate intakes

    Authors: , , , , - PLoS ONE 2017 cited by 435

  17. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 cited by 397

  18. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study

    Authors: , , , , , , , - Canadian Journal of Anesthesia/Journal canadien d anesthésie 2024 cited by 68

  19. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  20. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 267

  21. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

    Authors: , , - Journal of Clinical Oncology 2006 cited by 1,450

  22. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gero Kramer, Chris Logothetis, Fernando Cotait Maluf, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R. Padhani, Chris Parker, Colin C. Pritchard, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Oliver Sartor, Howard I. Scher, Avishay Sella, Neal D. Shore, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Ian F. Tannock, Bertrand Tombal, R. Valdagni, Thomas Wiegel, Aurelius Omlin - European Urology 2017 cited by 643

  23. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 217

  24. Accelerating precision medicine in metastatic prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2020 cited by 77